Famotidine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Famotidine: From [Regulatory Data Not Available] to Duodenogastric Reflux
One-Sentence Summary
Famotidine is a histamine H2-receptor antagonist (H2RA); no structured original-indication or license data is available for this drug in the current dataset, though the broader evidence base consistently documents its established use in acid-related upper GI disease (e.g., peptic ulcer, GERD). The TxGNN model’s top-ranked prediction for this candidate is Duodenogastric Reflux, with a 99.99% prediction score, but currently only 0 clinical trials and 2 publications support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Taiwan regulatory dataset shows 0 licenses on record for this product |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for famotidine is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information embedded elsewhere in the evidence pack’s clinical rationale fields, famotidine is a histamine H2-receptor antagonist — it blocks parietal cell H2 receptors to suppress gastric acid secretion, a mechanism well documented across the drug’s extensive peptic ulcer and GERD literature.
Duodenogastric reflux (DGR) involves acid-containing gastric contents refluxing alongside duodenal contents into the esophagus, so H2-mediated acid suppression could plausibly reduce the acid-related component of associated symptoms. However, per the evidence pack’s own rationale: “H2 blockade reduces gastric acid secretion, which may alleviate acid-related symptoms of reflux; however, duodenogastric reflux is primarily driven by bile/alkaline reflux rather than acid alone, so famotidine’s mechanism only partially addresses the underlying pathophysiology.”
In short, the mechanistic link is real but partial — famotidine targets only the acid component of a condition whose primary driver (bile/alkaline reflux) lies outside its mechanism of action. This is consistent with the model’s own moderate evidence level (L3) and early decision stage (S2, “Research Question”) rather than a stronger “Go” signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12532466 | 2003 | Cohort | World Journal of Gastroenterology | Investigated famotidine’s effect on gastroesophageal reflux (GER) and duodeno-gastro-esophageal reflux (DGER) in critically ill patients, exploring possible mechanisms and relevant contributing factors |
| 16259441 | 2004 | Review | Eksperimental’naia i Klinicheskaia Gastroenterologiia | Reviewed efficacy of famotidine 20 mg BID at early stages of gastroduodenal reflux disease, based on clinical and endoscopic findings (Savary-Miller grades 0–1) |
US Market Information
No regulatory license records are available for this drug — taiwan_regulatory.total_licenses = 0 and market status is “未上市” (Not Marketed). No product/dosage-form/indication table can be generated from current data.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications are flagged as a Blocking data gap, DG001 — this must be resolved before any Stage 1 safety review can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (duodenogastric reflux) has no registered clinical trials and only two non-RCT publications (a cohort study and a review), consistent with the model’s own L3/S2 “Research Question” classification. The mechanistic rationale is only partial, since DGR is primarily bile-driven rather than acid-driven.
To proceed, the following is needed:
- TFDA label (warnings/contraindications) — currently a Blocking gap (DG001)
- Famotidine mechanism of action documentation — currently a High-severity gap (DG002)
- Original indication / regulatory license data (none on record)
- Dedicated clinical trial evidence for famotidine in duodenogastric reflux specifically
- Consider evaluating peptic ulcer disease (rank 8, evidence level L1, 14+ trials) as a stronger-evidence alternative candidate from this same prediction set
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.